Literature DB >> 6810778

Valproic acid: metabolite concentrations in plasma and brain, anticonvulsant activity, and effects on GABA metabolism during subacute treatment in mice.

W Löscher, H Nau.   

Abstract

Mice were continuously treated with valproic acid (VPA) via the drinking water for period from 1 to 12 days. The daily drug intake varied between 500 and 580 mg/kg. However, due to the rapid elimination of VPA in this species average plasma concentrations of only 3-4 micrograms/ml VPA were present at 8:30 a.m., the time chosen for determinations. In the brain, VPA levels were about 10% of those in plasma. In regard to VPA metabolism the products of beta-oxidation 2-en-VPA 2-propyl-2-pentenoic acid) and 3-keto-VPA (2-propyl-3-oxopentanoic acid) proved to be the main metabolites in plasma although other (minor) metabolites of VPA were also present. The only metabolite of VPA detected in the brain was 2-en-VPA. VPA medication caused a significant increase in the threshold for electroconvulsions which was associated with a slight increment of brain GABA levels. The activity of glutamic acid decarboxylase was significantly elevated whereas GABA aminotransferase was not affected. After withdrawal of VPA, a delayed effect on seizure threshold was observed which extended to time periods where VPA could no longer be detected in the brain, but 2-en-VPA was still present.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6810778

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  10 in total

1.  Acute valproic acid overdose. Clinical course and pharmacokinetic disposition of valproic acid and metabolites.

Authors:  R E Dupuis; S N Lichtman; G M Pollack
Journal:  Drug Saf       Date:  1990 Jan-Feb       Impact factor: 5.606

2.  Valproic acid activates the PI3K/Akt/mTOR pathway in muscle and ameliorates pathology in a mouse model of Duchenne muscular dystrophy.

Authors:  Praveen B Gurpur; Jianming Liu; Dean J Burkin; Stephen J Kaufman
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

3.  Sodium valproate: effects on social behaviour and physical development in the mouse.

Authors:  J B Chapman; M G Cutler
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 4.  Effects of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain.

Authors:  W Löscher
Journal:  Neurochem Res       Date:  1993-04       Impact factor: 3.996

Review 5.  Formation of active metabolites of anticonvulsant drugs. A review of their pharmacokinetic and therapeutic significance.

Authors:  M J Eadie
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of valproic acid--1988.

Authors:  G Zaccara; A Messori; F Moroni
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

Review 7.  Differentiation between valproate-induced anticonvulsant effect, teratogenicity and hepatotoxicity. Aspects of species variation, pharmacokinetics, metabolism and implications of structural specificity for the development of alternative antiepileptic agents such as delta 2-valproate.

Authors:  H Nau; H Siemes
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

8.  Species differences in pharmacokinetics and drug teratogenesis.

Authors:  H Nau
Journal:  Environ Health Perspect       Date:  1986-12       Impact factor: 9.031

9.  On the Digital Psychopharmacology of Valproic Acid in Mice.

Authors:  John Samuel Bass; Anney H Tuo; Linh T Ton; Miranda J Jankovic; Paarth K Kapadia; Catharina Schirmer; Vaishnav Krishnan
Journal:  Front Neurosci       Date:  2020-11-06       Impact factor: 4.677

10.  Prophylactic Activation of Shh Signaling Attenuates TBI-Induced Seizures in Zebrafish by Modulating Glutamate Excitotoxicity through Eaat2a.

Authors:  James Hentig; Leah J Campbell; Kaylee Cloghessy; Mijoon Lee; William Boggess; David R Hyde
Journal:  Biomedicines       Date:  2021-12-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.